Loading organizations...

LTZ Therapeutics is a technology company.
LTZ Therapeutics is an immunotherapy-focused biotech developing innovative therapies for oncology and autoimmune diseases. Its core, a novel Myeloid Engager Platform, harnesses myeloid cell subsets, particularly macrophages, through reverse translational science. This platform activates innate receptors on myeloid cells via target-associated antigens, causing phagocytosis and potent target cell depletion.
Co-founded by Robert Li, PhD, Chairman and CEO, and Martin Treder, PhD, Chief Scientific Officer, their insight focused on myeloid cells' significant, untapped therapeutic potential. They recognized that precisely rebalancing the immune system through these cells could offer novel approaches for complex diseases where current treatments are insufficient.
LTZ Therapeutics aims to provide impactful solutions for patients suffering from cancer and autoimmune disorders. Its vision is to improve patient lives through this innovative platform, ultimately aiming to effectively eliminate cancer. Focusing on myeloid cell engagement, LTZ is committed to delivering bold solutions for critical unmet clinical needs.
LTZ Therapeutics has raised $47.0M across 3 funding rounds.
LTZ Therapeutics has raised $47.0M in total across 3 funding rounds.
LTZ Therapeutics has raised $47.0M in total across 3 funding rounds.
LTZ Therapeutics's investors include Lapam Capital, Qiming Venture Partners, K2 Venture Partners.
LTZ Therapeutics is a global biotechnology company specializing in immunotherapy, with a focus on developing innovative therapies for oncology and autoimmune diseases. Its core product platform, the Myeloid Engager Platform, leverages the biology of myeloid cell subsets—especially macrophages—to enhance anti-tumor immunity and overcome resistance in cancer treatment. LTZ aims to improve clinical outcomes for patients with high unmet medical needs by pioneering therapies that activate the immune system in novel ways. The company serves patients, healthcare providers, and the broader medical research community, positioning itself at the forefront of immuno-oncology innovation with promising growth fueled by strategic partnerships and funding rounds totaling over $47 million[1][2][3].
Founded in 2022 and headquartered in Redwood City, California, LTZ Therapeutics was established by Robert Li, who also serves as CEO. The company emerged from a vision to harness reverse translational science and emerging tumor microenvironment biology to develop next-generation immunotherapies. Early traction includes significant funding rounds and strategic collaborations with major pharmaceutical companies such as Eli Lilly and GSK, which have accelerated LTZ’s research and development efforts. These partnerships underscore LTZ’s evolution from a startup to a key player in the immunotherapy space, with operations spanning the US, China, and Germany[2][3][4].
LTZ Therapeutics is riding the wave of immuno-oncology and precision medicine, where understanding and manipulating the tumor microenvironment is critical. The timing is favorable due to advances in myeloid cell biology, growing unmet needs in cancer and autoimmune diseases, and increasing investment in biotech innovation. LTZ’s approach addresses limitations of existing immunotherapies by targeting myeloid cells, which play a pivotal role in immune regulation and tumor suppression. By advancing this frontier, LTZ influences the broader biotech ecosystem by expanding therapeutic modalities and fostering collaborations that accelerate drug development globally[1][3][4].
Looking ahead, LTZ Therapeutics is poised to advance its pipeline through clinical development, leveraging its strategic partnerships to bring novel myeloid engager therapies to market. Trends such as personalized medicine, deeper understanding of immune cell subsets, and integration of translational science will shape its journey. As LTZ matures, its influence may grow beyond oncology into autoimmune diseases, potentially transforming treatment paradigms. Continued innovation and collaboration will be key to realizing its mission of improving patient outcomes and possibly eliminating cancer in the long term[1][3][4].
LTZ Therapeutics has raised $47.0M across 3 funding rounds. Most recently, it raised $20.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $20.0M Series A | Lapam Capital | Qiming Venture Partners |
| May 1, 2023 | $10.0M Seed | Qiming Venture Partners | |
| Apr 1, 2022 | $17.0M Seed | K2 Venture Partners | Qiming Venture Partners |